GI-102 subcutaneous (SC): clinical trials recruiting now

Fewer than 3 recruiting trials found.

Phase breakdown

Conditions being studied

Recruiting trials involving GI-102 subcutaneous (SC)

• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations

Common questions

How many recruiting trials involve GI-102 subcutaneous (SC)?

1 recruiting trial across 12 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.